US OptionsDetailed Quotes
SLS241220C2500
- 0.10
- 0.000.00%
15min DelayClose Nov 22 16:00 ET
0.10High0.10Low
0.10Open0.10Pre Close18 Volume0 Open Interest2.50Strike Price180.00Turnover270.89%IV122.22%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier28DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.2626Delta0.3722Gamma11.70Leverage Ratio-0.0052Theta0.0002Rho3.07Eff Leverage0.0011Vega
Sellas Life Sciences Stock Discussion
Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences Group (NASDAQ: SLS) has received Rare Pediatric Disease Designation (RPDD) from the FDA for Galinpepimut-S (GPS) in treating pediatric acute myeloid leukemia (AML). GPS, an immunotherapeutic targeting Wilms Tumor-1, is currently in a Phase 3 REGAL trial for adult AML patients, with an inte...
Sellas Receives EMA Orphan Drug Designation for Sls009 for Treatment of Peripheral T-Cell Lymphomas
No comment yet